Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
All convalescent plasma..
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchConvalescent PlasmaConv. Plasma (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   All Outcomes    Recent:   
0 0.5 1 1.5 2+ Mortality -212% Improvement Relative Risk Mortality (b) -12% Ventilation -425% Progression, day 28 -425% primary Progression, day 14 -425% primary Conv. Plasma  CAPRI  LATE TREATMENT  DB RCT Is late treatment with convalescent plasma beneficial for COVID-19? Double-blind RCT 34 patients in the USA (June 2020 - April 2021) Higher mortality (p=0.47) and ventilation (p=0.21), not sig. c19early.org Hsue et al., NCT04421404, August 2021 Favors conv. plasma Favors control

Effects of COVID-19 Convalescent Plasma (CCP) on Coronavirus-associated Complications in Hospitalized Patients (CAPRI)

Hsue et al., NCT04421404, CAPRI, NCT04421404
Aug 2021  
  Post
  Facebook
Share
  Source   PDF   All   Meta
RCT 34 hospitalized patients in the USA, showing no significant difference with convalescent plasma treatment.
risk of death, 212.5% higher, RR 3.12, p = 0.47, treatment 1 of 16 (6.2%), control 0 of 18 (0.0%), continuity correction due to zero event (with reciprocal of the contrasting arm), day 28.
risk of death, 12.5% higher, RR 1.12, p = 1.00, treatment 1 of 16 (6.2%), control 1 of 18 (5.6%), all cause, day 28.
risk of mechanical ventilation, 425.0% higher, RR 5.25, p = 0.21, treatment 2 of 16 (12.5%), control 0 of 18 (0.0%), continuity correction due to zero event (with reciprocal of the contrasting arm), day 28.
risk of progression, 425.0% higher, RR 5.25, p = 0.21, treatment 2 of 16 (12.5%), control 0 of 18 (0.0%), continuity correction due to zero event (with reciprocal of the contrasting arm), death or mechanical ventilation, day 28, primary outcome.
risk of progression, 425.0% higher, RR 5.25, p = 0.21, treatment 2 of 16 (12.5%), control 0 of 18 (0.0%), continuity correction due to zero event (with reciprocal of the contrasting arm), death or mechanical ventilation, day 14, primary outcome.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Hsue et al., 23 Aug 2021, Double Blind Randomized Controlled Trial, placebo-controlled, USA, preprint, 1 author, study period 9 June, 2020 - 30 April, 2021, trial NCT04421404 (history) (CAPRI).
This PaperConv. PlasmaAll
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit